FutureGen Biopharmaceutical (Beijing) Co., Ltd

AbbVie is lifting its profit outlook and full-year 2024 guidance as its immunology blockbusters Skyrizi and Rinvoq beat quarterly revenue estimates, according to the company’s third-quarter filing . Global Skyrizi net revenues were $3.2 billion, an increase of about 50% from last year, while Rinvoq net revenues were $1.6 billion, an increase of about 45%. Thanks to the two blockbusters, AbbVie is raising its adjusted diluted EPS guidance for the year from between $10.67 and $10.87 to between $10.90 and $10.94, despite dipping sales of its once top-selling Humira. Global Humira net revenues for the quarter were $2.2 billion, a decrease of about 37% year-over-year. William Blair analysts wrote in a Wednesday note that Rinvoq and Skyrizi made up for Humira’s shortfall, with the two drugs beating their estimate by $185 million. AbbVie’s quarterly revenue of $14.4 billion also came in above the company’s previous guidance, consensus and the analysts’ estimate of $14.2 billion, which Blair analysts said was mainly driven by Rinvoq and Skyrizi. The trends seen in this latest filing are a “net positive, and we’re seeing overperformance from Skyrizi and Rinvoq more than offsetting the dynamics with Humira,” AbbVie CEO Rob Michael said in a Wednesday morning investor call. “We are starting to see this dynamic with the overall Humira molecule, where there is the switching that we’re seeing now to other mechanisms, including Skyrizi and Rinvoq, which is a long-term, very positive benefit,” Michael added. “Essentially two years after the US Humira [loss of exclusivity], we’ll be returning to robust top-line and bottom-line growth and really performance across many parts of the business, not just Skyrizi and Rinvoq.” The 15 deals the company has executed this year in its five key growth areas (eye care, immunology, oncology, neuroscience and aesthetics) are part of that return to growth, including a licensing deal with FutureGen Biopharmaceutical for an anti-TL1A antibody in inflammatory bowel disease and the acquisition of early-stage neuroscience biotech Aliada Therapeutics for $1.4 billion. Michael said in the investor call that the company would “focus more on early-stage opportunities to drive growth in the next decade.” “If we see an opportunity for differentiation in a large market with high unmet need like metabolics, we would consider pursuing it, especially if it can help drive growth in the next decade,” Michael said. “But again, it would be more opportunistic. We have to see differentiation, and right now it’s not our primary focus.”

DUBLIN--( BUSINESS WIRE )--The "Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering. Anti TIGIT antibodies have emerged a promising approach in cancer immunotherapy, offering new hope for patients with various types of cancers, particularly solid cancers. TIGIT (T cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor expressed on T cells and natural killer (NK) cells, playing a crucial role in modulating immune responses. By targeting TIGIT, researchers aim to enhance the immune system's ability to recognize and eliminate cancer cells, potentially revolutionizing cancer treatment strategies. The therapeutic potential of TIGIT as a target for cancer immunotherapy lies in its function as an immune checkpoint molecule. When TIGIT interacts with its ligands, such as CD155 and CD112, it suppresses T cell sand NK cell activation, potentially allowing cancer cells to evade immune surveillance. By blocking this interaction with anti-TIGIT therapeutic approaches, researchers hope to reinvigorate the immune response against tumors, leading to improved clinical outcome for cancer patients. Among the various approaches for targeting TIGIT, monoclonal antibodies have emerged as the most widely used and promising agents. These antibodies are designed to specifically bind to TIGIT, preventing its interaction with its ligands and thus releasing the "breaks" on the immune system. Their high specificity and relatively low toxicity of antibodies make them attractive candidates for clinical development. The field of anti-TIGIT antibody development has seen rapid progress, with over 50 candidates currently in clinical development. This robust pipeline underscores the significant interest and potential of this approach in cancer treatment. Among these, more than five anti TIGIT antibodies have advanced to phase 3 clinical trials, representing the most advanced stage of clinical development before potential regulatory approval. These include Vibostolimab, Tiragolumab and Ociperlimab, developed by the pharmaceutical marker leaders, Merck Genentech and BeiGene, respectively. These phase 3 clinical trials are assessing the safety and efficacy of these anti-TIGIT antibodies in various cancer types, with a particular focus on non-small cell lung cancer (NSCLC). The emphasis on NSCLC is not surprising, given its high prevalence and the need for more effective treatment options. NSCLC represents a significant portion of lung cancer cases and has shown promising responses to immunotherapy approaches in the past. Several key factors are driving the market potential of anti-TIGIT antibodies. Firstly, there remains a substantial unmet medical need in cancer treatment, especially for patients who do not respond to or develop resistance to existing immunotherapies. Anti-TIGIT antibodies offer a novel mechanism of action that could address these challenges. Moreover, these antibodies show promising results in combination with established therapies like PD-1/L1 inhibitors, potentially expanding the market for both drug classes and improving treatment outcomes. This becomes visible in Merck's vision of developing a coformulation of its anti-TIGIT antibody Vibostolimab with its blockbuster anti-PD-1 antibody pembrolizumab for the treatment of various solid tumors. The broad applicability of anti-TIGIT antibodies across various cancer forms presents another significant market opportunity. While a majority of clinical trials currently focus on NSCLC, many other ongoing clinical trials are exploring their efficacy in other solid cancers tumors and hematological malignancies, which could lead to multiple approved indications, consequently increasing the anti-TIGIT antibody market size. As evident from the examples above, the competitive landscape for the anti-TIGIT antibody market is dynamic, with major pharmaceutical companies and biotechnology firms vying for market share. While Vibostolimab leverages the company's strong position in the immuno-oncology market, another, Domvanalimab, being developed by Gilead Sciences and Arcus Biosciences, benefits from a partnership between a major pharmaceutical company and a competent biopharmaceutical company. In conclusion, anti-TIGIT antibodies not only represent a significant advancement in cancer immunotherapy, but also present many opportunities for drug development and market expansion. With its potential to address unmet medical needs, broad applicability and alignment with personalized medicine, this emerging class of drugs is poised to capture a substantial portion of cancer immunotherapy market. Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028 Report Highlights: Anti TIGIT Antibodies in Clinical Trials: > 50 Antibodies First Anti TIGIT Antibody to Get Approval Within Next 5 Years Global Anti TIGIT Antibodies Clinical Pipeline Insight by Company, Indication and Phase Insight on More Than 50 Anti TIGIT Antibodies in Clinical Trials Anti TIGIT Antibodies Market Trends by Indication & Country Global Anti TIGIT Antibodies Market Dynamics Key Topics Covered: 1. Introduction to Anti TIGIT Antibody 1.1 Overview 1.2 Mechanism of Anti TIGIT Antibodies 1.3 Clinical Approaches to Target TIGIT 2. Global Anti TIGIT Antibodies Clinical Trials Overview 2.1 By Company 2.2 By Country 2.3 By Indication 2.4 By Patient Segment 2.5 By Phase 3. Global Anti TIGIT Antibodies Clinical Pipeline By Company, Indication and Phase 3.1 Research 3.2 Preclinical 3.3 Phase I 3.4 Phase I/II 3.5 Phase II 3.6 Phase III 4. Global Anti TIGIT Antibodies Market Outlook 4.1 Current Clinical & Market Trends 4.2 Future Market Outlook 5. Anti TIGIT Antibodies Market Trends by Indication 5.1 Cancer 5.2 Autoimmune & Inflammatory Disorders 5.3 Microbial Infections 6. Anti TIGIT Antibodies Market by Country 6.1 US 6.2 China 6.3 South Korea 6.4 Australia 6.5 UK 7. Combinations Approaches for TIGIT Therapy 8. TIGIT Co Inhibition with PD1 or PDL1 9. Global Anti TIGIT Antibodies Market Dynamics 9.1 Market Drivers 9.2 Commercialization Challenges 10. Competitive Landscape Akeso Biopharma BeiGene Bio-Thera Solutions Biotheus Compugen FutureGen Biopharmaceutical Merck Sharp & Dohme Nanjing Sanhome Pharmaceutical OriCell Therapeutics Phio Pharmaceuticals Roche Shanghai Henlius Biotech Shanghai Junshi Biosciences Simcere Pharmaceutical Group Tasrif Pharmaceutical For more information about this report visit https://www.researchandmarkets.com/r/sebifx About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Roche's Chugai Pharmaceutical unit has inked a licensing agreement to secure Japanese rights to the Swiss pharma's investigational anti-TL1A antibody RG6631 for the treatment of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease. Under the deal announced Wednesday, Chugai will gain exclusive rights to develop and market the therapy in Japan, while Roche stands to receive an undisclosed upfront fee, alongside milestone payments. Highlighting a significant unmet treatment need for these intractable conditions, Chugai CEO Osamu Okuda said they “will work closely with Roche to bring RG6631 to patients with ulcerative colitis and Crohn’s disease as soon as possible.”According to Chugai, RG6631's unique action targeting inflammation and fibrosis through TL1A inhibition could deliver a promising new treatment option for IBD, with the potential to address other conditions as well.Chugai noted that the asset has demonstrated significant improvements on key endpoints, including clinical remission during both induction and maintenance phases of the global mid-stage TUSCANY-2 study in patients with moderate-to-severe ulcerative colitis. Roche is likely to initiate a Phase III study by the end of the year. A second mid-stage study involving patients with moderate-to-severe Crohn’s disease is also underway.The anti-TL1A space is abuzz, with several players battling it out in the IBD arena. AbbVie recently bagged global rights to FutureGen's preclinical candidate FG-M701 for $150 million upfront. Meanwhile, Teva and Sanofi have partnered on another anti-TL1A antibody, duvakitug (TEV-48574), for moderate-to-severe ulcerative colitis and Crohn’s disease, with topline mid-stage data expected in the last quarter of this year. Other prominent deals include Roche’s buyout of Roivant's Telavant (RVT-3101) for $7.1 billion after positive mid-stage data in ulcerative colitis, and Merck & Co. clinching tulisokibart (MK-7240) through its $10.8-billion acquisition of Prometheus.